CagriSema Post Hoc Data: 25% Weight Loss in Women as FDA Decision Looms
Two post hoc REDEFINE 1 analyses report 25.0% mean weight loss with investigational CagriSema in women at 68 weeks, with 23.1% to 26.7% across menopause subgroups, as an FDA decision looms.